Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Deoxyglucose SCHEMBL29105105 | 1.00 | LMNA (0.50) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| Deoxyglucose SCHEMBL307650 | 1.00 | LMNA (0.50) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| Deoxyglucose SCHEMBL148114 | 1.00 | LMNA (0.50) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| Deoxyglucose SCHEMBL2315642 | 1.00 | LMNA (0.50) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| Deoxyglucose SCHEMBL3019708 | 1.00 | LMNA (0.50) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| Deoxyglucose SCHEMBL2065929 | 1.00 | LMNA (0.50) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| Deoxyglucose SCHEMBL120125 | 1.00 | LMNA (0.50) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| Deoxyglucose SCHEMBL4480352 | 1.00 | LMNA (0.50) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| Deoxyglucose SCHEMBL10386937 | 1.00 | LMNA (0.50) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| Deoxyglucose SCHEMBL200714 | 1.00 | LMNA (0.50) | LMNAL3MBTL1TDP1PDE4AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115367745-B | Tungsten-containing substance hybridization and nitrogen-doped porous carbon material and preparation method thereof | 北京化工大学 | 2023-11-24 | — | — | CN | claimed |
| WO-2021238912-A1 | TRANSITION METAL COMPOUND-HYBRIDIZED AND NITROGEN-DOPED POROUS CARBON MATERIAL AND PREPARATION METHOD THEREFOR | 北京化工大学 | 2021-12-02 | — | — | WO | claimed |
| CN-111892047-A | Vanadium nitride hybrid and nitrogen-doped porous carbon material and preparation method and application thereof | 北京化工大学 | 2020-11-06 | — | — | CN | claimed |
| EP-2419478-B1 | FLUORESCENT IMAGING WITH SUBSTITUTED CYANINE DYES | LI COR INC (US) | 2018-02-28 | — | — | EP | claimed |
| EP-2630196-A1 | CYANINE DYES AND THEIR CONJUGATES | LI-COR, INC. (US) | 2013-08-28 | — | — | EP | claimed |
| WO-2012054749-A1 | CYANINE DYES AND THEIR CONJUGATES | LI-COR, INC. (US) | 2012-04-26 | — | — | WO | claimed |
| WO-2012054784-A1 | FLUORESCENT IMAGING WITH SUBSTITUTED CYANINE DYES | LI-COR, INC. (US) | 2012-04-26 | — | — | WO | claimed |
| EP-2419478-A2 | FLUORESCENT IMAGING WITH SUBSTITUTED CYANINE DYES | LI-COR, INC. (US) | 2012-02-22 | — | — | EP | claimed |
| WO-2010121163-A2 | FLUORESCENT IMAGING WITH SUBSTITUTED CYANINE DYES | LI-COR, INC. (US) | 2010-10-21 | — | — | WO | claimed |
| US-6353095-B1 | OCTULSONIC ACID AND DERIVATIVES WITH AZO AND AMIDE | THE SCRIPPS RESEARCH INSTITUTE | 2002-03-05 | — | — | US | claimed |
| WO-1993006227-A1 | KETOALDONIC ACIDS HAVING FORMED STEREOGENIC CENTERS OF R CONFIGURATION: METHODS AND COMPOSITIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1993-04-01 | — | — | WO | claimed |
| EP-4663014-A1 | CANCER MODEL ANIMAL AND METHOD FOR PRODUCING SAME | Orbio Corporation (JP) | 2025-12-17 | — | — | EP | disclosed |
| US-12414934-B2 | Combination therapies | Aardvark Therapeutics, Inc. (US) | 2025-09-16 | — | — | US | disclosed |
| WO-2024166912-A1 | CANCER MODEL ANIMAL AND METHOD FOR PRODUCING SAME | オルバイオ株式会社 | 2024-08-15 | — | — | WO | disclosed |
| WO-2024137472-A2 | COMBINATION THERAPIES | MEI PHARMA, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-1996035239-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-11-07 | — | — | WO | disclosed |
| WO-1993006227-A1 | KETOALDONIC ACIDS HAVING FORMED STEREOGENIC CENTERS OF R CONFIGURATION: METHODS AND COMPOSITIONS | THE SCRIPPS RESEARCH INSTITUTE (US) | 1993-04-01 | — | — | WO | disclosed |
| EP-0390783-A1 | METHOD FOR IMPROVING THE FEED CONVERSION EFFICIENCY OF MEAT-PRODUCING ANIMALS BY ORAL ADMINISTRATION OF 2-DEOXY-D-HEXOSE | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1990-10-10 | — | — | EP | disclosed |
| US-4937077-A | Method for improving feed conversion of meat-producing animals by oral administration of 2-deoxy-D-hexose | EASTMAN KODAK COMPANY (US) | 1990-06-26 | — | — | US | disclosed |
| WO-1989002224-A1 | METHOD FOR IMPROVING THE FEED CONVERSION EFFICIENCY OF MEAT-PRODUCING ANIMALS BY ORAL ADMINISTRATION OF 2-DEOXY-D-HEXOSE | EASTMAN KODAK COMPANY (US) | 1989-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12414934-B2 | Combination therapies | PCK2, PDK1, PCK1 | LMNA 3656/4885L3MBTL1 1851/4885TDP1 1949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.